Draft Scope Consultation
The National Institute for Health and Care Excellence (NICE) has been asked to consider an appraisal of guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs ID1658.
NICE invited organisations to take part in the consultation to discuss the draft remit and scope. The organisations selected as stakeholders are listed here and the draft scope that is being consulted on can be found here.
The consultation closes on Wednesday 18 December 2019. If you have any queries regarding this scoping exercise or would like to be involved you can contact Michelle Adhemar, Scoping Project Manager at email@example.com